G1 Therapeutics, Inc. (GTHX)

4,1300 +0,3600 (+9,55%) Alla chiusura: 04:00PM EDT

G1 Therapeutics, Inc.

700 Park Offices Drive
Suite 200
Research Triangle Park, NC 27709
United States
919 213 9835
https://www.g1therapeutics.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 100

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. John E. Bailey Jr.	CEO, President & Director	1,19M	N/D	1965
Dr. Rajesh K. Malik Ch.B., M.B., M.D.	Chief Medical Officer	653,56k	N/D	1959
Mr. Mark Avagliano	Chief Business Officer	663,73k	N/D	1976
Mr. John W. Umstead V	Chief Financial Officer	N/D	N/D	1985
Mr. Terry L. Murdock MSc	Chief Operating Officer	541,59k	606,34k	1960
Mr. William C. Roberts	Vice President of Investor Relations & Corporate Communications	N/D	N/D	1969
Ms. Monica Roberts Thomas	Chief Legal & People Officer	N/D	N/D	N/D
Mr. Evan Hicks M.B.A.	Vice President of Marketing	N/D	N/D	N/D
Mr. Andrew Perry	Chief Commercial Officer	568,6k	N/D	1974
Mr. Jeff Macdonald	Senior Director of Investor Relations & Corporate Communications	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer. The company has a license agreement with Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat various indication in humans; Incyclix for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses; and Simcere Pharmaceutical Co., Ltd for the development and commercialization of trilaciclib in all indications. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.

Governance aziendale

L'ISS Governance QualityScore di G1 Therapeutics, Inc. al 29 aprile 2024 è 7. I criteri di valutazione fondamentali sono revisione: 2; Consiglio di Amministrazione: 6; diritti degli azionisti: 8; retribuzione: 9.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.